Amphastar P (AMPH) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Total Assets Chart for Amphastar P
Amphastar P (AMPH) total assets for FY2025 were USD 1.6B, a 3.3% change from FY2024. Amphastar P's total assets grew from USD 317.5M in 2012 to USD 1.6B in 2025 (413.2% over 13 years). Total assets compound annual growth rate: 5-year CAGR of 20.9%, 10-year CAGR of 15.4%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $1.07B
- Implied Share Price
- $25.14
- Enterprise Value
- $1.66B
- Revenue (TTM)
- $730.02M
- EBITDA
- $194.51M
- Profit Margin
- 10.76%
- Trailing P/E
- 14.88
- Forward P/E
- 0.00
- Price/Book (MRQ)
- 1.63
- Price/Sales (TTM)
- 1.46
- EV/EBITDA
- 6.68
- EV/Revenue
- 2.29
- Dividend Yield
- —
- Book Value
- $18.06
- Free Cash Flow (FY2025)
- $121.23M
- Free Cash Flow Yield
- 11.34%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.